BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16842086)

  • 1. Coumarins as inhibitors of HIV reverse transcriptase.
    Kostova I
    Curr HIV Res; 2006 Jul; 4(3):347-63. PubMed ID: 16842086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors.
    Kostova I; Raleva S; Genova P; Argirova R
    Bioinorg Chem Appl; 2006; 2006():68274. PubMed ID: 17497014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
    Xu ZQ; Buckheit RW; Stup TL; Flavin MT; Khilevich A; Rizzo JD; Lin L; Zembower DE
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2179-84. PubMed ID: 9873509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the new nonnucleoside anti-HIV reverse transcriptase inhibitor-DCK].
    Guo HF; Xie L
    Yao Xue Xue Bao; 2008 Oct; 43(10):997-1002. PubMed ID: 19127862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plant Coumarins with Anti-HIV Activity: Isolation and Mechanisms of Action.
    Sharapov AD; Fatykhov RF; Khalymbadzha IA; Zyryanov GV; Chupakhin ON; Tsurkan MV
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives.
    Huang L; Yuan X; Yu D; Lee KH; Chen CH
    Virology; 2005 Feb; 332(2):623-8. PubMed ID: 15680427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coumarins as Potential Inhibitors of DNA Polymerases and Reverse Transcriptases. Searching New Antiretroviral and Antitumoral Drugs.
    Garro HA; Pungitore CR
    Curr Drug Discov Technol; 2015; 12(2):66-79. PubMed ID: 26179474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coumarin-based derivatives with potential anti-HIV activity.
    Xu Z; Chen Q; Zhang Y; Liang C
    Fitoterapia; 2021 Apr; 150():104863. PubMed ID: 33582266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
    Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordato-oblongum.
    Dharmaratne HR; Wanigasekera WM; Mata-Greenwood E; Pezzuto JM
    Planta Med; 1998 Jun; 64(5):460-1. PubMed ID: 9690350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
    Currens MJ; Mariner JM; McMahon JB; Boyd MR
    J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
    Xu H
    Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Xu ZQ; Flavin M
    Antivir Chem Chemother; 2000 Sep; 11(5):321-7. PubMed ID: 11142630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.
    Boyer PL; Currens MJ; McMahon JB; Boyd MR; Hughes SH
    J Virol; 1993 Apr; 67(4):2412-20. PubMed ID: 7680393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Zhou T; Xie L
    Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.